This is what we are up against
Each day, 56 people in Australia are diagnosed with breast cancer and 9 people die to this disease. Each death is one too many, and research is critical to better understand breast cancer and ultimately save lives lost to this disease.
Where your money goes
When you Step Up to Breast Cancer by completing 56km throughout August, the funds you raise for the National Breast Cancer Foundation (NBCF) support world-class breast cancer research. Ongoing research is critical to better understand, prevent, detect, treat and stop breast cancer and ultimately create better treatment outcomes for the 56 Australians diagnosed with breast cancer every day.
The more we raise, the more research we can fund to drive progress towards our vision of Zero Deaths from breast cancer. We need your help to fund research into:
Meet some of our NBCF-funded researchers
By taking part in Step Up to Breast Cancer and raising funds for NBCF, you're funding world-class breast cancer research focused on better understanding how to prevent and detect breast cancer early, how to stop the progression and recurrence of breast cancer and how to effectively treat hard-to-treat and metastatic breast cancers - research that ultimately saves lives. The more we raise, the more research we can fund.
Here are just a few of the inspiring research projects underway.
Professor Geoffrey Lindeman
Towards more effective therapies for people with relapsed breast cancer
Estrogen Receptor Positive (ER+) breast cancer accounts for the highest number of breast cancer relapses and deaths. Professor Geoff Lindeman and his team at WEHI aim to test new drugs that target BCL2, a cancer survival protein that enables cancer cells in metastatic ER+ breast cancer to stay alive. They will develop optimal treatment strategies to kill these cancer cells safely and effectively.
Associate Professor Tatyana Chtanova
Harnessing the innate immune system to develop new therapies for Triple Negative Breast Cancer (TNBC)
Triple Negative Breast Cancer (TNBC) is an aggressive subtype with limited treatment options. Associate Professor Tatyana Chtanova and her team at UNSW Sydney and the Garvan Institute of Medical Research aim to provide a new treatment option for TNBC by developing and optimising a novel immunotherapy that uses bacteria to reprogramme tumour-promoting immune cells to destroy cancer cells.
